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 ABSTRACT 
 
Purpose: To evaluate long-term outcome of myeloablative allogeneic stem cell transplantation (allo-
SCT) (MAC) vs reduced-intensity allo-SCT (RIC) in patients with relapsed/refractory Hodgkin’s 
lymphoma (HL) in recent years. 
Patients and Methods: Three hundred and twelve patients (63 MAC and 249 RIC) with 
relapsed/refractory HL who received allo-SCT between 2006 and 2010 and were reported to the EBMT 
Database were included in the study. 
Results: With a median follow-up for alive patients of 56 (26 – 73) months, there were no significant 
differences in non-relapse mortality (NRM) between MAC and RIC. Relapse rate (RR) was somewhat 
lower in the MAC group (41% vs 52% at 24 months, p=0.16). This lower RR translated into a marginal 
improvement in event-free survival (EFS) for the MAC group (48% vs 36% at 24 months, p=0.09) with 
no significant differences in overall survival (73% for MAC 62% for RIC at 24 months, p=0.13). 
Multivariate analysis after adjusting for disease status at the time of allo-SCT showed that the use of 
MAC was of borderline statistical significance for predicting a lower RR and EFS [HR 0.7, 95%CI (0.5 – 
1.0), p=0.1] and [HR 0.7, 95%CI (0.5 – 1.0), p=0.07] respectively after allo-SCT. 
Conclusion: With modern transplant practices, the NRM associated with MAC for HL has strongly 
decreased, resulting into non-significant improvement of EFS because of a somewhat better disease 
control compared to RIC transplants. The intensity of conditioning regimens should be considered when 
designing individual allo-SCT strategies or clinical trials in patients with relapsed/refractory HL. 
n = 244 words 
 
 INTRODUCTION 
Most patients with Hodgkin lymphoma (HL) achieve sustained remissions following first-line 
chemotherapy (CT) with or without consolidation radiotherapy (RT). 1,2 However, studies report that 5–
10% are refractory to first-line therapy and up to 30% of patients will relapse. Autologous stem cell 
transplantation (ASCT) is considered to be the standard of care for patients with relapsed / refractory 
HL.3-5   
 
Prognosis of patients relapsing after ASCT is poor.6 Allogeneic stem cell transplant (allo-SCT) is the 
standard of care for young patients with chemosensitive disease at the time of transplant and a HLA 
compatible donor available.7 The use of myeloablative conditioning protocols (MAC) was associated to 
an exceedingly high non-relapse mortality (NRM) of about 50% in the earlier days.8,9 The Lymphoma 
Working Party (LWP) of the European Group for Blood and Marrow Transplantation (EBMT) 
demonstrated that reduced intensity conditioning protocols (RIC) were able to significantly decrease 
NRM after the procedure.10 Nevertheless, the use of less intense CT has also been associated to a 
high relapse rate (RR) after transplant.11-15  
 
The objective of this retrospective registry analysis was to analyze the long-term outcome of patients 
with relapsed / refractory HL being treated either with MAC vs RIC in recent years and the potential 
clinical benefit of MAC, assuming that the improvement in HLA typing molecular techniques, supportive 
measures and expertise in the transplant centers over time would have potentially decreased NRM 
after the procedure, thus potentially improving survival outcomes by the already known reduced RR in 
this setting.    
 
 
 PATIENTS AND METHODS 
Data Source 
EBMT is a voluntary organization comprising more than 500 transplant centers mainly from Europe. 
Accreditation as a member centre requires submission of minimal essential data (MED-A form) from all 
consecutive patients to a central registry in which patients may be identified by the diagnosis of 
underlying disease and type of transplantation. MED-A data is updated annually. Informed consent for 
transplantation and data collection was obtained locally according to regulations applicable at the time 
of transplantation. Since January 1 2003, all transplant centers have been required to obtain written 
informed consent prior to data registration with the EBMT following the Helsinki Declaration 1975. 
 
Patient Eligibility 
Inclusion criteria for this study were adult patients with relapsed / refractory HL who underwent allo-SCT 
from an HLA identical related donor (HLA id sib) or well-matched unrelated donor (WMUD, 10 out of 10 
antigens) between January 2006 and December 2010 and were reported to the EBMT registry. Only 
first allo-SCT were included. Tandem and cord blood transplants were excluded as well as recipients of 
syngeneic transplants. Minimum data required for the inclusion of a patient were age, sex, histological 
diagnosis, date of diagnosis, details of prior high-dose therapy, disease status at transplantation, details 
of conditioning regimen, date of transplantation, donor relationship, date of follow-up, disease status at 
follow-up, date of disease progression or death, and cause of death.  
 
 
 
 Definitions  
Histological diagnosis was based on local review. Disease status at transplantation was classified as 
chemosensitive disease including all patients who had shown at least a partial remission (PR) and 
chemoresistant disease including patients with primary refractory disease, refractory relapse or 
untreated relapse. Patients who survived more than 90 days after allo-SCT without evidence of tumor 
were classified as having experienced complete remission (CR). PR was defined as a ≥ 50% reduction 
of all pre-transplantation measurable disease for at least 1 month. Patients achieving less than 50% 
tumor reduction were considered non-responders. Intensity of conditioning regimens was defined as 
previously published.16 In addition to that, details in terms of drugs used and total doses administered 
for each individual patient were specifically reviewed by the principal investigator of the study in order to 
double check the definition of MAC vs RIC. 
 
Statistical analysis  
Primary end points studied were overall survival (OS) and event free survival (EFS) after allo-SCT. OS 
was defined as the time from allo-SCT to death from any cause and EFS was defined as the time from 
allo-SCT to relapse or progressive disease or death from any cause, whatever came first. Probabilities 
of OS were calculated using the Kaplan-Meier estimate and compared using the log-rank test. 
Multivariate comparisons of OS times and estimations of hazard ratios were calculated using Cox 
regression models. Secondary endpoints were RR and NRM, and incidences of acute and chronic 
graft-versus-host disease (GVHD). RR was calculated as time from allo-SCT to relapse or progression, 
NRM was calculated as time from allo-SCT to death in the absence of prior relapse or progression. 
Relapse and NRM events were considered as competing risks. For cumulative incidence of chronic 
GVHD (cGVHD), death was considered as a competing risk. Cumulative incidence curves for relapse, 
cGVHD and NRM incidences were compared using the Gray’s test. Multivariate analysis for relapse 
 and NRM incidences were performed using a competing risk proportional subdistribution hazards 
regression model. Median observation time was calculated by the reversed Kaplan-Meier estimate. 
Database follow up was closed in December 2015. All statistical analyses were performed using R 
2.15.3 (R Foundation for Statistical Computing, Vienna, Austria, http://www.R‐ project.org). All 
statistical tests were 2-sided with a P value <0.05 considered to indicate a statistically significant result.   
 
RESULTS 
A group of 312 patients fulfilling the inclusion criteria were identified; 63 had received a MAC and the 
remaining 249, a RIC approach. Most important characteristics at the time of transplantation are shown 
in Table 1a. Table 1b indicates clinical characteristics of patients receiving allo-SCT as a first 
transplant  (data included in supplemental files). Details of conditioning regimens are included in Table 
2. 
GVHD 
There were no differences in the incidence of grades II-IV acute GVHD (aGVHD) and chronic GVHD 
(cGVHD) between both groups of patients. Multivariate analysis indicated that age of the recipient over 
30 years, male sex, MAC protocols and the use of total body irradiation (TBI) in the conditioning 
regimen were independent adverse prognostic factors for the development of cGVHD (Table 3a). 
 
NRM 
NRM was 9%, 12% and 13% at 1, 2 and 5 years, respectively for the whole group of patients (Figure 
1a), with no significant differences between MAC (5%, 11% and 13% at 1, 2 and 5 years) and RIC 
 patients (10%, 11% and 12% at 1, 2 and 5 years) (Figure 1b). The multivariate analysis adjusted on 
age did not show the presence of any independent adverse prognostic factor for NRM (Table 3a). 
 
Relapse / Progression 
One hundred and forty-five patients (53% of the whole group; 46% for MAC vs 55% for RIC) 
experienced disease relapse / progression. Median [interquartile range (IQR)] time to relapse was 8.7 
(3.1 – 12.3) months in the MAC group vs 6.1 (3.5 – 14.3) months in the RIC group. Cumulative 
incidence of relapse was 38%, 50% and 59% at 1, 2 and 5 years, respectively (Figure 1a) [33%, 41% 
and 50% for MAC patients and 39%, 52% and 60% for RIC patients at 1,2 and 5 years (Figure 1b)]. 
Multivariate analysis indicates that disease status at the time of transplantation was the only significant 
risk factor for disease relapse (Table 3a)  
 
Event-free survival 
The estimated EFS was 53%, 39% and 30% at 1, 2 and 5 years, respectively (Figure 2a). Conditioning 
intensity did impact in EFS, which was better although non-significantly different in the MAC group 
(48% vs 36% at 24 months, p=0.09) (Figure 2b). Disease status had a major impact in the outcome of 
the procedure (Figure 2c). Multivariate analysis adjusted on disease status, age and use of TBI 
indicated that the use of MAC protocols was associated with a non-significant EFS benefit (Table 3a).   
 
Overall survival  
After a median follow-up for survivors of 56 months (IQR 26 to 73 months), 153 patients were alive, 36 
(58%) in the MAC group and 116 (48%) in the RIC. one The estimated OS was 73%, 64% and 45% at 
 1, 2 and 5 years, respectively (Figure 3a). There were no significant OS differences between both 
groups of patients (73% for MAC 62% for RIC at 24 months, p=0.13) (Figure 3b). Chemosensitive 
disease at allo-SCT was the only independent prognostic factor for OS in the multivariate analysis after 
adjusting for age (Table 3a, Figure 3c).   
 
Multivariate analysis for patients being treated with allo-SCT as first SCT 
Multivariate analysis restricted to the population of patients treated with allo-SCT as first transplantation 
procedure (Table 3b, data included in supplemental files) indicated that MAC protocols were 
associated with a lower although non-significant RR that was translated into an improvement in both 
EFS and OS. The intensity of the conditioning regimen was not a prognostic factor for NRM (Table 3b, 
data included in supplemental files).  
 
DISCUSSION 
Despite the advent of novel potent pharmacological treatment options, 21-25 allo-SCT remains a 
reasonable treatment option for those patients who relapse or progress after an ASCT. Nevertheless, 
there are still many unsolved questions in this setting; the intensity of the conditioning regimen to 
optimize long-term results of the procedure is one of them. While MAC allo-SCT has been classically 
associated to an unacceptably high NRM, the major obstacle for a long-term remission in the RIC 
scenario is the high relapse risk. Since most of the analyses looking at the outcome after MAC allo-SCT 
deal with patients allografted more than 15 years ago; 8-10 the hypothesis of the present study was that 
advances in HLA typing and selection of the appropriate donor in the unrelated setting, better selection 
of the allotransplant candidates, better supportive measures, and more experienced clinical teams 
might have improved the outcome of MAC allo-SCT.  
  
Several lines of evidence have demonstrated that in HL, conditioning intensity matters. In our previous 
study, the multivariate analysis restricted to the RIC group indicated that RR was higher in those 
patients receiving TBI-containing regimens.10 In children and adolescents treated with a allo-SCT PFS 
after RIC was significantly lower than after MAC because of the higher RR after RIC; NRM was 
independent on the intensity of the conditioning regimen used.17 Finally, excellent results with the 
combination of BEAM conditioning and alemtuzumab-based GVHD prophylaxis as first transplant in 
patients with relapsed / refractory HL have been reported by Thomson and Peggs.18  
 
With all this background in mind, we decided to perform a second retrospective analysis in patients with 
relapsed/refractory HL looking at the long-term outcome of RIC vs MAC. In this study a more recent 
population of patients thus, more representative of our present clinical practice was included. Clinical 
characteristics of the allografted population of patients were not so different from our previous analysis. 
In both retrospective comparisons the RIC group was significantly older, the evolution of the underlying 
disease before transplant was also longer and a higher percentage of them had eventually failed a prior 
ASCT. While in the first retrospective comparison NRM at 1 year was 46% and 23% for MAC and RIC, 
respectively, in this second one, NRM at 1 year was remarkably low with 9% for both groups of 
patients. NRM after allo-SCT for HL has improved over time independently of the conditioning used, but 
this improvement is most evident in the MAC group. Of note, 21 of the 63 HL patients conditioned with 
MAC (33%) were treated with BEAM-Alemtuzumab that has been classically associated with a low 
NRM. 19 In contrast, and in keeping with our previous analysis where 57% of the RIC patients relapsed 
vs 30% in the MAC group, 10 HL relapse remains the most important cause of allo-SCT failure in 
patients being treated with a RIC. In the present analysis, disease relapse was also more frequent in 
the RIC group (55% vs 46%). Thus EFS was superior with MAC in the multivariate analysis although 
this difference was not statistically significant. Moreover, MAC patients also enjoyed a non-significant 
 improvement in OS. The analysis of those patients with relapsed/refractory disease that were treated 
with an allogeneic approach as first transplant, indicate a better EFS and OS for MAC recipients vs RIC 
recipients. RR was lower in the MAC group but did not reach statistical significance in the multivariate 
analysis.  
 
Unfortunately, this analysis is hampered by its retrospective nature and the fact that both groups of 
patients are not comparable in terms of disease and patients’ characteristics before allo-SCT. Still the 
decision on the intensity of the conditioning regimen to be used in this setting is not completely settled 
down. In the absence of prospective clinical trials, the possibility to modify the pre-existing conditioning 
protocols with the introduction of new drugs in order to increase the effectiveness but not the toxicity of 
the combination is a concept that could be taken into consideration. 
 
The unique clinical benefit of an allo-SCT in the lymphoma setting is the combination of the 
effectiveness of high-dose chemotherapy with the graft-versus-lymphoma effect. Although retrospective 
studies 10-12,14 as well as prospective clinical trials 15 and evidence from DLI studies20,21 have indicated 
the existence of a beneficial graft-versus-HL effect, its clinical impact seems to be limited. Fine-tuning of 
the efficacy of the conditioning regimen may help to set the stage for GVL activity becoming effective in 
HL. Novel targeted drugs could further optimize the outcome of HL allotransplants by improving disease 
status prior to and disease control post allo-SCT. 22-26 
 
In addition to the inherent pitfalls associated to the retrospective nature of this analysis, one has to 
acknowledge that the relapsed / refractory setting has changed in patients with HL with the advent of 
the new drugs. Brentuximab vedotin (BV) granted an accelerated approval by the FDA and the EMA in 
2011 and 2012, respectively for those patients with HL relapsing after an ASCT; overall response rate 
of 76% with a PET negative CR of 34% in this population of patients. 22 Although the curative potential 
 of BV is still unknown, a 4-year follow up study indicates that there are long-term disease free survivors 
after stopping the drug. 23 More recently, the anti-PD1 ligands (nivolumab and pembrolizumab), have 
given interesting results in relapsed / refractory HL patients, even in those failing BV. 24,25 The decision 
to whether allograft every single patient with HL relapsing or progressing after an ASCT or to delay 
allotransplants to a later phase of the disease remains to be elucidated but, from a daily practice point 
of view, many centers are still allograting young patients with chemosensitive disease demonstrated 
after a short course of BV. This strategy most probably will improve results of the allogeneic procedure 
by taking patients into the transplant in better clinical conditions and also in a better disease status. 26   
 
In conclusion, this study suggests that with current transplant practices, the NRM associated with MAC 
has strongly decreased, resulting into a non-significant improvement in EFS. The intensity of 
conditioning regimens should be considered when designing individual allo-SCT strategies or clinical 
trials in patients with relapsed / refractory HL. 
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 Table 1a.  Characteristics of the whole series of patients. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Table 1a. Whole series of patients. 
 
Characteristic 
 
Whole Group (n = 312) 
 
MAC (n = 63) 
 
RIC (n = 249) 
 
P value 
Sex 
   Male 
   Female 
 
172 (55%) 
140 (45%) 
 
38 (60%) 
25 (40%) 
 
139 (54%) 
114 (46%) 
 
NS 
Age at diagnosis, years (median, IQR) 28 (22 – 36) 26 (21 – 33) 27.8 (22 – 37) NS 
 
Age at allo-SCT, years (median, IQR) 
 
31 (25 –40) 
 
27.1 (24 – 36) 
 
32 (25 – 41) 
 
0.04 
 
Dx –Allo-SCT, months (median, IQR) 
 
32 (20 – 54) 
 
21 (13 – 29) 
 
35.6 (24 – 56) 
 
0.0002 
≥ 3 prior lines of therapy before allo-SCT  180 (57%) 25 (40%) 155 (62%) 0.08 
Prior ASCT   
   Yes 
   No 
 
172 (55%) 
140 (44%) 
 
17 (27%) 
46 (73%) 
 
155 (62%) 
90 (38%) 
 
 
0.00002 
Stem cell source 
   BM 
   PB 
 
37 (12%) 
275 (88%) 
 
9 (14%) 
54 (86%) 
 
28 (11%) 
221 (89%) 
 
NS 
Type of donor 
   HLA Id-sib 
   MUD 
 
272 (87%) 
40 (13%) 
 
61 (97%) 
2 (3%) 
 
211 (85%) 
38 (15%) 
 
0.01 
Disease status at allo-SCT 
 Sensitive Disease 
   Refractory Disease 
 
151 (51%) 
153 (49%) 
 
29 (46%) 
34 (54%) 
 
132 (53%) 
118 (47%) 
 
NS 
Performance Status at allo-SCT 
   0 – 1 
   ≥ 2 
   Unknown  
 
224 (72%) 
65 (20%) 
23 (8%) 
 
40 (63%) 
17 (27%) 
6 (10%) 
 
184 (74%) 
48 (19%) 
17 (7%) 
 
NS 
TBI in the conditioning regimen 
   Yes 
   No  
 
48 (15%) 
264 (85%) 
 
16 (25%) 
47 (75%) 
 
32 (13%) 
217 (87%) 
 
0.02 
 
 Allo-SCT. Allogeneic stem cell transplantation; MAC. Myeloablative conditioning regimen; RIC. Reduced intensity 
conditioning regimen; Dx. Diagnosis; ASCT. Autologous stem cell transplantation; BM. Bone marrow; PB. Peripheral blood; 
HLA id sib. HLA identical sibling donor; WMUD. Well matched unrelated donor; TBI. Total body irradiation; NS. Not 
significant. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Table 2.  Details of conditioning protocols. 
 
Conditioning Regimen MAC (n = 63) RIC (n = 249) 
BEAM 
BEAM-A 
BuCy +/- VP-16 
CyTBI 
FluBu +/- Others 
FluCy +/- Others 
FluMel +/- Others 
FluTBI (2 Gys) 
10 (17%) 
21 (33%) 
16 (25%) 
16 (25%) 
0 
0 
0 
0 
0 
0 
0 
0 
50 (20%) 
33 (13%) 
134 (54%) 
32 (13%) 
 
BEAM. BCNU, etoposide, ara-c and melphalan; A. Alemtuzumab; BuCy +/- VP-16. Busulfan and cyclophosphamide +/- 
etoposide; CyTBI. Cyclophosphamide and total body irradiation; FluBu. Fludaraine and busulfan; FluCy. Fludarabine and 
cyclophosphamide; FluMel. Fludarabine and melphalan; FluTBI. Fludarabine and total body irradiation. 
 
 
 
 
 
 
 
 
 
 
 
 
  
Table 3a. Multivariate analysis for cGHVD, NRM, RR, EFS and OS: whole series of patients. 
 
Chronic graft versus host disease 
Variable HR 95%CI p value 
Time from diagnosis to SCT 
over 20 months 
1.54 0.96 – 2.48 0.07 
Age over 30 years 0.65 0.43 – 0.98 0.03 
Male vs Female 1.62 1.07 – 2.46 0.02 
MAC vs RIC 0.55 0.32 – 0.95 0.03 
TBI vs no TBI 2.21 1.33 – 3.7 0.002 
Matched unrelated vs 
Identical sibling 
0.55 0.27-1.11 0.098 
Refractory disease  vs 
sensitive disease 
1.04 0.68-1.58 0.846 
 
Non-Relapse Mortality 
Variables HR 95%CI P value 
TBI vs no TBI 1.84 0.80 – 4.25 0.15 
Refractory disease vs 
sensitive disease 
0.98 0.50 – 1.94 0.60 
MAC vs RIC 0.79 0.33-1.89 0.60 
 
Relapse Rate 
Variables HR 95%CI P value 
Refractory disease vs 
sensitive disease 
1.92 1.36 – 2.71 0.0002 
MAC vs RIC 0.72 0.47-1.09 0.127 
 
 
 
  
 
Event Free Survival 
Variables HR 95%CI P value 
Refractory disease vs 
sensitive disease 
1.65 1.21 – 2.25 0.001 
MAC vs RIC 0.70 0.48 – 1.04 0.07 
TBI vs no TBI 1.28 0.84-1.89 0.217 
 
Overall Survival 
Variable HR 95%CI p value 
MAC vs RIC 0.72 0.47 – 1.10 0.13 
Refractory disease vs 
sensitive disease 
1.70 1.19 – 2.41 0.002 
Male vs female 1.29 0.92-1.81 0.128 
Stratified on age (cut off of 30 years) 
HR. Hazard ratio; 95%CI. 95% confidence interval; MAC. Myeloablative conditioning regimen; RIC. Reduced intensity 
conditioning regimen; TBI. Total body irradiation.  
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
Figure legends. 
 
Figure 1. Non-relapse mortality and relapse incidence after allogeneic stem cell transplantation. 
Figure 1a. Results from the whole group of patients included in the analysis (n = 312) 
Figure 1b. Comparison between MAC (n = 63) and RIC (n = 249) groups. 
 
Figure 2. Progression free survival after allogeneic stem cell transplantation. 
 Figure 2a. Results from the whole series. 
 Figure 2b. Comparison between MAC and RIC. 
 Figure 2c. Impact of disease status at the time of allo-SCT in the PFS after the procedure. 
 
Figure 3. Overall survival after allogeneic stem cell transplantation. 
 Figure 3a. Results from the whole series. 
 Figure 3b. Comparison between MAC and RIC groups. 
 Figure 3c. Impact of disease status at allo-SCT in the OS after the procedure. 
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Figure 1b. 
 
 
 
 
 
 
 
  
 
Figure 2a. 
 
 
 
 
 
 
 
  
 
Figure 2b. 
 
 
 
 
 
 
 
  
 
 
Figure 2c.  
 
 
 
 
 
 
  
 
 
Figure 3a. 
 
 
 
 
 
 
  
 
Figure 3b. 
 
 
 
 
 
 
 
  
 
 
Figure 3c. 
 
 
 
 
 
 
  
 
 
 
 
 
